{"created":"2023-07-27T06:29:20.381776+00:00","id":14109,"links":{},"metadata":{"_buckets":{"deposit":"7676d752-e246-4be9-ac76-112bf57b7038"},"_deposit":{"created_by":3,"id":"14109","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14109"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014109","sets":["1132:1133:1134"]},"author_link":["97","1166","20454","361"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-04-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"増刊1","bibliographicPageEnd":"557","bibliographicPageStart":"554","bibliographicVolumeNumber":"25","bibliographic_titles":[{"bibliographic_title":"泌尿器外科 = Japanese journal of urological surgery"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"前立腺癌に対するホルモン療法は1941年のHugginsら1)の報告以来約70年経過した今も前立腺癌治療において重要な位置を占めている. 当初は外科的去勢術やエストロゲン剤による治療からはじまったが, その後LH-RH analogが開発され, 一時的去勢による補助的ホルモン療法や間欠的使用が可能になった. 1982年にLabrieらは前立腺癌に対するホルモン療法は単に去勢のみでは不十分であるとし, アンチアンドロゲン剤との併用の必要性を提唱した2). これが現在までcombined androgen blockade(CAB)療法として広く用いられてきた. 最近, 前立腺癌細胞内でのアンドロゲン代謝系をターゲットとした新たな治療法が開発されるなど, ホルモン療法に大きな転換期が訪れている. 一方, ホルモン療法の負の面として, アンドロゲン低下に伴い様々な身体・臓器機能低下が起きうることが問題となってきており, その対策が課題となっている.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"医学図書出版"}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.igakutosho.co.jp/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 医学図書出版 | 許可を得て登録"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10064459","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0914-6180","subitem_source_identifier_type":"ISSN"}]},"item_4_text_2":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_text_value":"[特集]泌尿器科の変遷:過去から未来へ7.前立腺癌"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"並木, 幹夫"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"溝上, 敦"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"小中, 弘之"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"北川, 育秀"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-NAMIKI-M-554.pdf","filesize":[{"value":"5.5 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-NAMIKI-M-554.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14109/files/ME-PR-NAMIKI-M-554.pdf"},"version_id":"efc56736-23ca-43dc-9f7d-6a314bfe2618"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"限局性および局所進行前立腺癌に対するホルモン療法の現状と展望","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"限局性および局所進行前立腺癌に対するホルモン療法の現状と展望"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14109","relation_version_is_last":true,"title":["限局性および局所進行前立腺癌に対するホルモン療法の現状と展望"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:52:50.702299+00:00"}